Review of the literature on major mental disorders in adult patients with mitochondrial diseases

O Fattal, K Budur, AJ Vaughan, K Franco - Psychosomatics, 2006 - Elsevier
Mitochondria are intracellular organelles crucial to the production cellular energy. Mitochondrial
disease results from a malfunction in this biochemical cascade. These disorders can …

[HTML][HTML] Measuring cognition and function in the preclinical stage of Alzheimer's disease

…, LJ Bain, R Brashear, K Budur… - Alzheimer's & Dementia …, 2018 - Elsevier
The Alzheimer's Association's Research Roundtable met in November 2016 to explore how
best to measure changes in cognition and function in the preclinical stage of Alzheimer's …

[HTML][HTML] New applications of disease genetics and pharmacogenetics to drug development

…, AR Hariri, KE Asin, DG Crenshaw, K Budur… - Current opinion in …, 2014 - Elsevier
… Author links open overlay panel Allen D Roses 1 2 , Ann M Saunders 2 , Michael W Lutz 2
, Nanyin Zhang 3 , Ahmad R Hariri 2 , Karen E Asin 4 , Donna G Crenshaw 1 , Kumar Budur 4 …

[HTML][HTML] Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

…, A Kikuchi, T Kimber, T Kimura, R Kumar… - The Lancet …, 2021 - thelancet.com
Background Progressive supranuclear palsy is a neurodegenerative disorder associated with
tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to …

[HTML][HTML] Sleep disorders in substance abusers: how common are they?

Y Mahfoud, F Talih, D Streem, K Budur - Psychiatry (Edgmont), 2009 - ncbi.nlm.nih.gov
Substance abuse is a major public health problem with high morbidity and mortality. Comorbid
disorders are suspected to cause a high relapse rate. Subjects with sleep disorders tend …

Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study

…, HV Kalluri, B Rendenbach-Mueller, K Budur… - Brain, 2023 - academic.oup.com
Tau accumulation in patients with Alzheimer’s disease tracks closely with cognitive decline
and plays a role in the later stages of disease progression. This phase 2 study evaluated the …

Advancing combination therapy for Alzheimer's disease

SP Salloway, J Sevingy, K Budur… - … Research & Clinical …, 2020 - Wiley Online Library
The study of Alzheimer's disease (AD) has led to an increased understanding of the multiple
pathologies and pathways of the disease. As such, it has been proposed that AD and its …

[HTML][HTML] Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson's disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 …

…, B Bergmans, F Bergquist, M Bouchard, K Budur… - Neurology and …, 2023 - Springer
Introduction Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD)
prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day …

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active …

MJ Soileau, J Aldred, K Budur, N Fisseha… - The Lancet …, 2022 - thelancet.com
Background Levodopa is the most effective symptomatic therapy for Parkinson's disease,
but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral …

[HTML][HTML] Prevalence and correlates of alpha-delta sleep in major depressive disorders

…, CL Rodriguez, K Budur - Innovations in Clinical …, 2011 - ncbi.nlm.nih.gov
Objective. Major depressive disorder is associated with sleep disturbances. An
electroencephalographic pattern of alpha wave intrusion in delta wave sleep (alpha-delta sleep) is …